OSUR — OraSure Technologies Inc
NASDAQ · Health Care · Health Care
- Latest Close
- $3.16
- 30-Day Move
- +26.9%
- Market Cap
- $217M
- Shares Outstanding
- 69,130,000
- P/B Ratio
- 0.51
- ROE
- -20.2%
Analyst consensus: Buy · 9 analysts
OraSure Technologies Inc
A read-only Alphactor snapshot forOraSure Technologies Inc. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of2026-04-21
Topline snapshot
Latest Close
$3.16
30-Day Move
+26.9%
Market Cap
$217M
Shares Outstanding
69,130,000
P/B Ratio
0.51
ROE
-20.2%
$3.16
+26.9%last 90 delayed daily bars
90D High
$3.45
90D Low
$2.33
Avg Volume
521,875
Gross margin is running at 42.2%, which gives a quick read on operating quality before you open the full model.
Net margin is -59.8%, useful for comparing OSUR against peers in Health Care.
OSUR is up 26.9% over the last 30 trading days shown on this page.
Latest operating income is $-68M, which helps anchor the headline ratios with an actual earnings figure.
Composite Fair Value
$11.01
Rule of 40
-84.4%
Latest Close
$3.16
30-Day Move
+26.9%
Market Cap
$217M
Shares Outstanding
69,130,000
P/B Ratio
0.51
ROE
-20.2%
ROA
-17.1%
Gross Margin
42.2%
Operating Margin
-62.6%
Net Margin
-59.8%
Debt / Equity
0
Current Ratio
6.58
Latest Revenue
$115M
Revenue
$115M
Gross Profit
$48M
Operating Income
$-68M
Net Income
$-69M
Gross Margin
4222.0%
Net Margin
-5976.0%
Current Ratio
6.58
Debt / Equity
0.00
Fair Value
$11.01
Upside / Downside
+248.4%
Signal
Undervalued
Implied Growth
--
EV/Rev
$11.01
Growth Assumption
-10.0%
Discount Rate
10.5%
Terminal Growth
2.0%
Base FCF
--
Valuation spread
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Negative FCF — company is cash-flow negative. Reverse DCF requires positive cash flows.
Altman Z
1.88
Grey
Piotroski
2
Weak (0-3)
Cash Conversion
0.71x
Rule of 40
-84.4%
Concerning
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $387M | $-5M | $-17M | $-111M |
| 2023-12-31 | $405M | $43M | $54M | $131M |
| 2024-12-31 | $186M | $-24M | $-20M | $24M |
| 2025-12-31 | $115M | $-68M | $-69M | $-53M |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
Buy Value
$326,242.02
Sell Value
$0
Buys
5
Sells
0
Buy Value
$326,242.02
Sell Value
$0
Buy/Sell Ratio
5.00x
After signup
The full app goes deeper on insider behavior
Inspect longer insider history, recurring buyers and sellers, and the broader transaction context beyond this snapshot.
Continue into deeper institutional and alternative-data views once you sign up.
| Date | Name | Type | Shares | Price |
|---|---|---|---|---|
| 2026-03-26 | Boyd Steven Kyle | F | 1,416 | $3.10 |
| 2026-03-26 | Boyd Steven Kyle | A | 5,246 | $3.10 |
| 2026-03-20 | McGrath Kenneth J | Buy | 32,300 | $2.93 |
| 2026-03-20 | EGLINTON MANNER CARRIE | Buy | 32,300 | $2.93 |
| 2026-03-13 | McGrath Kenneth J | Buy | 22,021 | $3.00 |
| 2026-03-13 | EGLINTON MANNER CARRIE | Buy | 22,022 | $3.00 |
| 2026-03-02 | Anthony Michele Marie | A | 42,982 | $0.00 |
| 2026-03-02 | McGrath Kenneth J | A | 88,348 | $0.00 |
BlackRock
Filed 2024-05-10
$78M
--
Vanguard Group
Filed 2025-05-09
$15M
+1.4%
Renaissance Technologies
Filed 2025-05-14
$9M
--
Geode Capital Management
Filed 2025-11-12
$6M
-0.0%
4
Consensus
Buy—
—
—
9
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.